WO2007012974A2 - Cyclodextrin nanotechnology for ophthalmic drug delivery - Google Patents

Cyclodextrin nanotechnology for ophthalmic drug delivery Download PDF

Info

Publication number
WO2007012974A2
WO2007012974A2 PCT/IB2006/002769 IB2006002769W WO2007012974A2 WO 2007012974 A2 WO2007012974 A2 WO 2007012974A2 IB 2006002769 W IB2006002769 W IB 2006002769W WO 2007012974 A2 WO2007012974 A2 WO 2007012974A2
Authority
WO
WIPO (PCT)
Prior art keywords
cyclodextrin
drug
eye
composition according
aqueous
Prior art date
Application number
PCT/IB2006/002769
Other languages
English (en)
French (fr)
Other versions
WO2007012974A3 (en
Inventor
Thorsteinn Loftsson
Einar Stefansson
Original Assignee
Oculis Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oculis Ehf filed Critical Oculis Ehf
Priority to EP06808951.5A priority Critical patent/EP1909755B1/en
Priority to PL06808951T priority patent/PL1909755T3/pl
Priority to ES06808951.5T priority patent/ES2675043T3/es
Publication of WO2007012974A2 publication Critical patent/WO2007012974A2/en
Publication of WO2007012974A3 publication Critical patent/WO2007012974A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the invention relates to cyclodextrin nanotechnology for drug delivery, more especially, to cyclodextrin formulations that can effectively deliver therapeutically effective drug amounts to the posterior section of the eye.
  • Cyclodextrins are cyclic oligosaccharides with a hydrophilic outer surface and a somewhat lipophilic central cavity. In aqueous solutions cyclodextrins are able to form inclusion complexes with many drugs by taking up a drug molecule, or more frequently some lipophilic moiety of the molecule, into the central cavity. This property has been utilized for drug formulation and drug delivery purposes. Formation of drug/cyclodextrin inclusion complexes, their effect on the physicochemical properties of drugs and usage in pharmaceutical products has been reviewed (Loftsson, Jarho et al. 2005). For a variety of reasons, including cost, formulation bulk and toxicology, the amount of cyclodextrin that can be included in drug formulations is limited.
  • the polymers increase the apparent stability constant of the drug/cyclodextrin complexes through formation of ternary drug/cyclodextrin/polymer complexes. Thus, on the average 40 to 50% less CD is needed when a polymer is present. Furthermore, some studies have shown that drug bioavailability from formulations containing a ternary drug/cyclodextrin/polymer complex is greater than from a comparable drug/cyclodextrin binary complex. In general, the water-soluble polymers improve both pharmaceutical and biological properties of drug/cyclodextrin complexes. Until recently it was generally believed that most drugs form simple 1:1 or 1 :2 drug/cyclodextrin inclusion complexes.
  • the critical cyclodextrin concentration of the aggregate formation is about 5.4% (w/v) (Duan, Zhao et al. 2005; Loftsson, Ossurard ⁇ ttir et al. 2005).
  • Lysine, polyvinylpyrrolidone and magnesium ions formed non-inclusion complexes resulting in formation of ternary, quaternary and even pentenary complexes in aqueous solutions (Duan, Zhao et al. 2005).
  • the diameter of these self-assembling aggregates has been estimated to be about 6 nm (aggregates of two or three drug/cyclodextrin complexes).
  • Cyclodextrins make it possible to formulate lipophilic drugs in aqueous eye drop solutions. This may be useful for the formulation of a variety of lipophilic drugs that have not been available as eye drops or only in suboptimal formulations. Steroid drugs, including corticosteroids, are a good example of such drugs. They are lipophilic and have only been available in eye drops as prodrugs or suspensions with limited concentration and bioavailability. Likewise, carbonic anhydrase inhibitors have only been available as oral formulation or aqueous eye drop formulation where the pH has to be adjusted to non-physiological values.
  • cyclodextrins With cyclodextrins it is possible to increase the concentration of dissolved drug and enhance drug bioavailability and create formulations that offer more effective and less frequent treatment schedules.
  • Drug elimination from pre-corneal area After ocular instillation, aqueous eye drops will mix with the tear fluid and be dispersed over the eye surface.
  • various pre-corneal factors will limit the ocular absorption by shortening comeal contact time of applied drags. The most important factors are the drainage of installed solution, non-corneal absorption and induced lacrimation. These factors, and the corneal barrier itself, will limit penetration of a topically administered ophthalmic drug. As a result, only few percentages of the applied dose are delivered into the intraocular tissues.
  • the major part (50-100%) of the administered dose will be absorbed into the systemic drug circulation which can cause various side effects.
  • an applied eye-drop 25-50 ⁇ l
  • the greater part of the drag solution is rapidly drained from the eye surface and the solution volume returns to the normal resident tear volume of about 7 ⁇ l.
  • the pre-ocular solution volume remains constant, but drug concentration decreases due to dilution by tear turnover and corneal and non-corneal absorption.
  • the value of the first-order rate constant for the drainage of eye drops from precorneal area is typically about 1.5 min "1 in humans. Normal tear turnover is about 1.2 ⁇ l/min in humans (Sugrue 1989).
  • the precorneal half-life of topically applied drugs is between 1 and 3 minutes.
  • Drug delivery to the posterior segments of the eye is important for treating several disorders such as age-related macular degeneration, diabetic retinopathy, retinal venous occlusions, retinal arterial occlusion, macular edema, postoperative inflammation, uveitis retinitis, proliferative vitreoretinopathy and glaucoma. Due to anatomic membrane barriers (i.e. cornea, conjunctiva and sclera) and the lachrymal drainage it can be quite challenging to obtain therapeutic drug concentrations in the posterior parts of the eye after topical drag administration.
  • anatomic membrane barriers i.e. cornea, conjunctiva and sclera
  • lachrymal drainage it can be quite challenging to obtain therapeutic drug concentrations in the posterior parts of the eye after topical drag administration.
  • drugs can be delivered to the eye via invasive methods such as direct drug injection into the vitreous humor or subconjunctival injections. Invasive methods can cause discomfort for the patient and can also lead to complications that are even more serious than the disease being treated. In most cases, topical or systemic administration is used to treat posterior diseases despite limited bioavailability from these formulations.
  • Microspheres and nanoparticles are colloidal drug carriers in the micro- and submicron range. These systems were developed to overcome solubility problems of poorly soluble drugs as well as for long acting injectable depot formulations and specific drug targeting options. These carriers (without cyclodextrin) were also evaluated for ophthalmic drug delivery purposes over the past 25 years (Zimmer and Kreuter 1995). Nanoparticles formed by surface active cyclodextrin derivatives have been studied but not specifically for topical drug delivery to the eye. Previously, aqueous eye drop suspensions have been studied but in these studies the particles were obtained by including insufficient amounts of cyclodextrin to the formulations, that is the solid particles consisted of relatively pure drug and not drug/cyclodextrin complexes (H.O.
  • the present inventors have found that the generally acceptable dogma detailed above in the section entitled Drug delivery to the posterior segments of the eye, that is, that eye drops are ineffective in delivering drugs to the posterior segments, in particular to the retina, vitreous and optic nerve, is not correct.
  • the present inventors have invented a drug delivery platform that can effectively deliver drugs, such as dexamethasone, to the posterior segments of the eye in therapeutically effective concentrations by topical administration to the eye.
  • Retinal diseases may accordingly effectively be treated by drugs delivered topically to the eye as eye drop suspensions or as solid water-soluble particles.
  • the invention thus provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es) and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid, the cyclodextrin comprising at least one natural cyclodextrin selected from the group consisting of ⁇ -cyclodextrin, ⁇ -cyclodextrin and ⁇ -cyclodextrin.
  • the aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.
  • the invention provides a new use for cyclodextrin in the preparation of an aqueous eye suspension as defined in the preceding paragraph, for drug delivery to the posterior segments of the eye in a therapeutically effective amount for treating a condition of said segment.
  • the invention provides a method for treating a condition of a posterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said posterior segment a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is an aqueous suspension, preferably an aqueous drop formulation, but alternatively an aqueous gel or mist/spray formulation, comprising drug, cyclodextrin and water, the formulation having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid
  • the invention also provides a nasal composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 1% (w/v) to about 95% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 5% (w/v) to about 99% (w/v) of the drug as solid drug/cyclodextrin particles, the particle size of the particles in the solid phase being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in nasal mucous fluid within about 24 hours after application to the nasal mucosa, the cyclodextrin comprising at least one natural cylodextrin selected from the group consisting of ⁇ -cyclodextrin, ⁇ -cyclodextrin and ⁇ -cyclodextrin.
  • the nasal composition can be in the form
  • the invention provides a new use for cyclodextrin in the preparation of an aqueous nasal suspension as defined in the preceding paragraph, for drug delivery to the nose in a therapeutically effective amount for drugs suited to nasal administration.
  • the invention also provides a method for treating a condition susceptible to treatment by nasal drug administration comprising applying to the nasal mucosa a nasal composition as defined above.
  • the present invention provides a method for not only treating a condition of the posterior segment of the eye but also a method for treating the anterior segment of the eye, and a method for treating a condition of both the posterior and anterior segments of the eye, comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is an aqueous suspension as defined above.
  • the invention also provides the ophthalmic composition as a powder which is a lyophilized or spray-dried form of the ophthalmic suspension form as defined above.
  • the powder form of the ophthalmic composition is useful in treating the same ophthalmic conditions treated with the aqueous suspension form of the ophthalmic composition.
  • the invention further provides the nasal composition as a powder which is a lyophilized or spray-dried form of the aqueous suspension form of the nasal aqueous suspension as defined above.
  • the powder form of the nasal composition is useful in treating the same conditions treated with the aqueous suspension form of the nasal composition.
  • FIG. 1 is a plot of dexamethasone blood levels, in ng/g, against time post treatment, in minutes, following intranasal, intravenous and ophthalmic administration to rabbits of a 0.5% dexamethasone eye drop solution prepared as described in Experiment 1 below (prior art randomly methylated ⁇ - cyclodextrm/dexamethasone solution) .
  • FIG. 2 is a bar graph showing topical and systemic absorption in rabbits in various tissues of the eye after topical administration to the eye of a 0.5% dexamethasone eye drop solution prepared as described in Experiment 1 (prior art randomly methylated ⁇ -cyclodextrin/dexamethasone solution).
  • FIG. 3 is a plot of dexamethasone concentrations in blood (in ng/g, mean + standard deviation) against time post treatment, in minutes, after topical administration to the eyes of rabbits of 0.5% dexamethasone/ randomly methylated ⁇ -cyclodextrin (RM ⁇ CD) eye drop solution (prior art solution) (•) or of 1.5% dexamethasone/ ⁇ -cyclodextrin ( ⁇ CD) eye drop suspension (suspension of the invention) (o).
  • RM ⁇ CD randomly methylated ⁇ -cyclodextrin
  • ⁇ CD 1.5% dexamethasone/ ⁇ -cyclodextrin
  • FIG. 4 is a bar graph showing relative amounts of dexamethasone reaching the various eye tissues determined 2 hours after topical administration to the eye of aqueous 1.5% dexamethasone/ ⁇ cyclodextrin eye drop suspension or aqueous 1.5% dexamethasone/randomly methylated ⁇ -cyclodextrin eye drop solution to rabbits.
  • FIG. 5 is a bar graph showing the distribution of particle size in aqueous
  • FIG. 6 is a bar graph showing the distribution of particle size in aqueous 1.5% dexamethasone/ ⁇ -cyclodextrin (Y CD) eye drop suspension (suspension of the invention), after storage for 7 months, for a representative 50 particles.
  • Y CD dexamethasone/ ⁇ -cyclodextrin
  • FIG. 7 is a phase-solubility diagram of hydrocortisone in pure aqueous ⁇ - cyclodextrin solution or suspension (depending on the concentration) at room temperature.
  • An ocular condition is a disease, ailment or other condition which affects or involves the eye or one of the parts or regions of the eye.
  • the eye includes the eyeball and the tissues and fluids which constitute the eyeball, the periocular muscles (such as the oblique and rectus muscles) and the portion of the optic nerve which is within or adjacent to the eyeball.
  • An anterior ocular condition is a disease, ailment or condition which affects or which involves an anterior (i.e. front of the eye) ocular region or site, such as a periocular muscle, an eye lid or an eye ball tissue or fluid which is located anterior to the posterior wall of the lens capsule or ciliary muscles.
  • an anterior ocular condition primarily affects or involves one or more of the following: the conjunctiva, the cornea, the anterior chamber, the iris, the posterior chamber (behind the retina but in front of the posterior wall of the lens capsule), the lens, or the lens capsule, and blood vessels and nerves which vascularize or innervate an anterior ocular region or site.
  • a posterior ocular condition is a disease, ailment or condition which primarily affects or involves a posterior ocular region or site such as the choroid or sclera (in a position posterior to a plane through the posterior wall of the lens capsule), vitreous, vitreous chamber, retina, optic nerve (i.e. the optic disc), and blood vessels and nerves which vascularize or innervate a posterior ocular region or site.
  • a posterior ocular condition can include a disease, ailment or condition such as, for example, macular degeneration (such as non-exudative age-related macular degeneration and exudative age-related macular degeneration); choroidal neovascularization; acute macular neuroretinopathy; macular edema (such as cystoid macular edema and diabetic macular edema); Behcet's disease, retinal disorders, diabetic retinopathy (including proliferative diabetic retinopathy); retinal arterial occlusive disease; central retinal vein occlusion; uveitic retinal disease; retinal detachment; ocular trauma which affects a posterior ocular site or location; a posterior ocular condition caused by or influenced by an ocular laser treatment; posterior ocular conditions caused by or influenced by a photodynamic therapy; photocoagulation; radiation retinopathy; epiretinal membrane disorders; branch retinal vein occlusion; anterior ischemic
  • An anterior ocular condition can include a disease, ailment or condition such as, for example, aphakia; pseudophakia; astigmatism; blepharospasm; cataract; conjunctival diseases; conjunctivitis; corneal diseases; corneal ulcer; dry eye syndromes; eyelid diseases; lacrimal apparatus diseases; lacrimal duct obstruction; myopia; presbyopia; pupil disorders; refractive disorders and strabismus.
  • Glaucoma can also be considered to be an anterior ocular condition because a clinical goal of glaucoma treatment can be to reduce a hypertension of aqueous fluid in the anterior chamber of the eye (i.e. reduce intraocular pressure).
  • the present invention is concerned with and directed to ophthalmic compositions for topical drug delivery to the eye(s) and to methods for the treatment of an ocular condition, such as an anterior ocular condition or a posterior ocular condition or an ocular condition which can be characterized as both an anterior ocular condition and a posterior ocular condition.
  • an ocular condition such as an anterior ocular condition or a posterior ocular condition or an ocular condition which can be characterized as both an anterior ocular condition and a posterior ocular condition.
  • Macular degeneration such as age-related macular degeneration ("AMD) is a leading cause of blindness in the world. It is estimated that thirteen million Americans have evidence of macular degeneration. Macular degeneration results in a breakdown of the macula, the light-sensitive part of the retina responsible for the sharp, direct vision needed to read or drive. Central vision is especially affected.
  • Macular degeneration is diagnosed as either dry (atrophic) or wet (exudative).
  • the dry form of macular degeneration is more common than the wet form of macular degeneration, with about 90% of AMD patients being diagnosed with dry AMD.
  • the wet form of the disease usually leads to more serious vision loss.
  • Macular degeneration can produce a slow or sudden painless loss of vision.
  • the cause of macular degeneration is not clear.
  • the dry form of AMD may result from the aging and thinning of macular tissues, depositing of pigment in the macula, or a combination of the two processes. With wet AMD, new blood vessels grow beneath the retina and leak blood and fluid. This leakage causes retinal cells to die and creates blind spots in central vision.
  • Macular edema can result in a swelling of the macula.
  • the edema is caused by fluid leaking from retinal blood vessels. Blood leaks out of the weak vessel walls into a very small area of the macula which is rich in cones, the nerve endings that detect color and from which daytime vision depends. Blurring then occurs in the middle or just to the side of the central visual field. Visual loss can progress over a period of months. Retinal blood vessel obstruction, eye inflammation, and age-related macular degeneration have all been associated with macular edema. The macula may also be affected by swelling following cataract extraction. Symptoms of ME include blurred central vision, distorted vision, vision tinted pink and light sensitivity.
  • Causes of ME can include retinal vein occlusion, macular degeneration, diabetic macular leakage, eye inflammation, idiopathic central serous chorioretinopathy, anterior or posterior uveitis, pars planitis, retinitis pigmentosa, radiation retinopathy, posterior vitreous detachment, epiretinal membrane formation, idiopathic juxtafoveal retinal telangiectasia, Nd: YAG capsulotomy or iridotomy.
  • Some patients with ME may have a history of use of topical epinephrine or prostaglandin analogs for glaucoma.
  • the first line of treatment for ME is typically anti-inflammatory drops topically applied.
  • Macular edema is a non-specific response of the retina to a variety of insults. It is associated with a number of diseases, including uveitis, retinal vascular abnormalities (diabetic retinopathy and retinal vein occlusive disease), a sequelae of cataract surgery (post-cataract cystoid macular edema), macular epiretinal membranes, and inherited or acquired retinal degeneration.
  • Macular edema involves the breakdown of the inner blood retinal barrier at the level of the capillary endothelium, resulting in abnormal retinal vascular permeability and leakage into the adjacent retinal tissues. The macula becomes thickened due to fluid accumulation resulting in significant disturbances in visual acuity. Macular edema may occur in patients having diseases causing cumulative injury over many years, such as diabetic retinopathy, or as a result of more acute events, such as central retinal vein occlusion or branch retinal vein occlusion.
  • macular edema resolves spontaneously or with short-term treatment.
  • Therapeutic choices for macular oedema depend on the cause and severity of the condition.
  • intravitreal injection of a drug has shown promising results, but due to the short intraocular half-life of the active agents, such as glucocorticoids (approximately 3 hours), intravitreal injections must be frequently repeated to maintain a therapeutic drug level. In turn, this repetitive process increases the potential for side effects such as retinal detachment, endophthalmitis, and cataracts.
  • active agents such as glucocorticoids (approximately 3 hours)
  • Potent corticosteroids such as dexamethasone suppress inflammation by inhibiting edema, fibrin deposition, capillary leakage and phagocytic migration, all key features of the inflammatory response.
  • Corticosteroids prevent the release of prostaglandins, some of which have been identified as mediators of cystoid macular edema.
  • corticosteroids including dexamethasone have been shown to inhibit the expression of vascular endothelial growth factor (VEGF), a cytokine which is a potent promoter of vascular permeability.
  • VEGF vascular endothelial growth factor
  • dexamethasone to date, by conventional routes of administration, has yielded limited success in treating retinal disorders, including macular edema, largely due to the inability to deliver and maintain adequate quantities of the drug to the posterior segment without resultant toxicity.
  • topical administration of dexamethasone only about 1% reaches the anterior segment, and only a fraction of that amount moves into the posterior segment.
  • intravitreal injections of dexamethasone have been used, the exposure to the drug is very brief as the half-life of the drug within the eye is approximately 3 hours.
  • Periocular and posterior sub- Tenon's injections of dexamethasone also have a short term treatment effect.
  • Glaucoma means primary, secondary and/or congenital glaucoma.
  • Primary glaucoma can include open angle and closed angle glaucoma.
  • Secondary glaucoma can occur as a complication of a variety of other conditions, such as injury, inflammation, vascular disease and diabetes.
  • “Inflammation-mediated” in relation to an ocular condition means any condition of the eye which can benefit from treatment with an anti-inflammatory agent, and is meant to include, but is not limited to, uveitis, macular edema, acute macular degeneration, retinal detachment, ocular tumors, fungal or viral infections, multifocal choroiditis, diabetic uveitis, proliferative vitreoretinopathy (PVR), sympathetic opthalmia, Vogt Koyanagi-Harada (VKH) syndrome, histoplasmosis, and uveal diffusion.
  • PVR proliferative vitreoretinopathy
  • VKH Vogt Koyanagi-Harada
  • Injury or “damage” are interchangeable and refer to the cellular and morphological manifestations and symptoms resulting from an inflammatory- mediated condition, such as, for example, inflammation.
  • Posterior ocular condition means a disease, ailment or condition which affects or involves a posterior ocular region or site such as choroid or sclera (in a position posterior to a plane through the posterior wall of the lens capsule), vitreous, vitreous chamber, retina, optic nerve (i.e. the optic disc), and blood vessels and nerve which vascularize or innervate a posterior ocular region or site.
  • a posterior ocular region or site such as choroid or sclera (in a position posterior to a plane through the posterior wall of the lens capsule), vitreous, vitreous chamber, retina, optic nerve (i.e. the optic disc), and blood vessels and nerve which vascularize or innervate a posterior ocular region or site.
  • “Steroidal anti-inflammatory agent” and “anti-inflammatory steroid” and “glucocorticoid” are used interchangeably herein, and are meant to include steroidal agents, compounds or drugs which reduce inflammation when administered at a therapeutically effective level.
  • “Therapeutic levels” or “therapeutic amount” or “effective amount” means an amount or a concentration of an active agent that has been locally delivered to an ocular region that is appropriate to safely treat an ocular condition so as to reduce or inhibit or prevent a symptom of an ocular condition.
  • the active agent for use in the ophthalmic compositions of the invention can be selected from the group consisting of ace-inhibitors, endogenous cytokines, agents that influence basement membrane, agents that influence the growth of endothelial cells, adrenergic agonists or blockers, cholinergic agonists or blockers, aldose reductase inhibitors, analgesics, anesthetics, antiallergics, anti-inflammatory agents, steroids (such as steroidal anti-inflammatory agents), antihypertensives, pressors, antibacterials, antivirals, antifungals, antiprotozoals, anti-infective agents, antitumor agents, antimetabolites, and antiangiogenic agents.
  • the active agent can be, for example, cortisone, dexamethasone, fluocinolone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, or any antiinflammatory derivative thereof.
  • the ophthalmic compositions of the invention typically vary according to the preferred drug release profile, the particular active agent used, the condition being treated, and the medical history of the patient.
  • Active agents that may be used include, but are not limited to, ace-inhibitors, endogenous cytokines, agents that influence basement membrane, agents that influence the growth of endothelial cells, adrenergic agonists or blockers, cholinergic agonists or blockers, aldose reductase inhibitors, analgesics, anesthetics, antiallergics, anti-inflammatory agents, antihypertensives, pressors, antibacterials, antivirals, antifungals, antiprotozoals, anti-infectives, antitumor agents, antimetabolites, and antiangiogenic agents.
  • the active agent is methotrexate.
  • the active agent is retinoic acid.
  • the anti-inflammatory agent is a nonsteroidal anti-inflammatory agent.
  • Nonsteroidal anti-inflammatory agents that may be used include, but are not limited to, aspirin, diclofenac, flurbiprofen, ibuprofen, ketorolac, naproxen, and suprofen.
  • the antiinflammatory agent is a steroidal anti-inflammatory agent.
  • the steroidal anti-inflammatory agents that may be used in the ocular compositions and methods of the invention include, but are not limited to, 21- acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, etiprednol dicloacetate, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl,
  • cortisone, dexamethasone, fluocinolone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone, and their derivatives are preferred steroidal anti-inflammatory agents.
  • the steroidal anti-inflammatory agent is dexamethasone.
  • the composition includes a combination of two or more steroidal anti- inflammatory agents.
  • buffering agents and preservatives may be employed.
  • Preservatives which may be used include, but are not limited to, sodium bisulfite, sodium bisulfate, sodium thiosulfate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric nitrate, methylparaben, polyvinyl alcohol and phenylethyl alcohol.
  • buffering agents that may be employed include, but are not limited to, sodium carbonate, sodium borate, sodium phosphate, sodium acetate, sodium bicarbonate, and the like, as approved by the FDA for the desired route of administration.
  • Electrolytes such as sodium chloride and potassium chloride may also be included in the formulation.
  • Examples of medical conditions of the eye which may be treated by the compositions and methods of the invention include, but are not limited to, uveitis, macular edema, macular degeneration, retinal detachment, ocular tumors, fungal or viral infections, multifocal choroiditis, diabetic retinopathy, proliferative vitreoretinopathy (PVR), sympathetic opthalmia, Vogt Koyanagi-Harada (VKH) syndrome, histoplasmosis, uveal diffusion, and vascular occlusion.
  • uveitis macular edema
  • macular degeneration macular degeneration
  • retinal detachment ocular tumors
  • fungal or viral infections multifocal choroiditis
  • PVR proliferative vitreoretinopathy
  • VKH Vogt Koyanagi-Harada
  • histoplasmosis histoplasmosis
  • uveal diffusion uveal diffusion
  • compositions are particularly useful in treating such medical conditions as uveitis, macular edema, vascular occlusive conditions, proliferative vitreoretinopathy (PVR), and various other retinopathies. See also the discussion of drugs and conditions hereinabove.
  • This invention relates to enhanced topical drug delivery into eye obtained by maintaining the tear fluid saturated with the drug for enhanced duration of time;
  • the driving force for one-dimensional diffusion is the gradient of chemical potential along the direction of diffusion, that is, spontaneous flow from a region of higher chemical potential to one of lower chemical potential.
  • Maximum chemical potential of a given drug is obtained when it forms a saturated solution, for example when the drug forms a saturated solution in the tear fluid.
  • the drug molecules When the tear fluid is saturated with the drug then the drug molecules have maximum tendency to partition from the fluid into cornea, slera and other tissues that are in contact with the tear fluid. These tissues form hydrophilic or lipophilic membranes. Drug diffusion through these membranes is also driven by the gradient of chemical potential within the membrane and, thus, high drug concentration at the membrane surface will enhance drug delivery through the membrane.
  • drugs that are administered to the eye as aqueous eye drop solutions will rapidly be diluted and washed from the eye surface by the constant flow of tear fluid. Drug dilution on the eye surface reduces drug flow from the surface into the eye.
  • Many ophthalmic drugs are lipophilic compounds with limited aqueous solubility. Such drugs are sometimes administered as aqueous eye drop suspensions and this will result in somewhat sustained drug concentrations at the eye surface.
  • due to their low water-solubility their absorption from the eye surface into the eye will be dissolution rate limited, that is drug absorption into the eye will be hampered by the slow dissolution of the solid drug.
  • lipophilic drugs as more water-soluble drug/cyclodextrin complexes will increase the dissolution rate of the solid drug in the tear fluid preventing dissolution rate limited drug absorption.
  • Particles in an ophthalmic eye drop suspension are washed more slowly than dissolved drug molecules from the eye surface, partly due to inherent mucoadhesion of the particles. The particles attach themselves to the mucus fraction of the tear film.
  • the amount of dissolved drug in the tear fluid can be controlled by combining natural cyclodextrins and more water-soluble cyclodextrin derivatives in the aqueous eye drop formulation.
  • hydrophilic cyclodextrins such as the natural ⁇ -, ⁇ - and ⁇ -cyclodextrin and their hydroxypropyl and sulfobutyl ether derivatives
  • cyclodextrins have negligible effect on the chemical composition and structure of the lipophilic membranes. Enhanced absorption is obtained through introduction of more favorable physicochemical conditions for passive drug diffusion.
  • J P - C Aq (1)
  • P the permeability coefficient of the drug through the lipophilic membrane
  • C A q the drug concentration at the aqueous exterior.
  • the permeability coefficient is defined as: D - K
  • D is the diffusion coefficient of the drag within the membrane
  • K is the partition coefficient of the drug from the aqueous tear fluid into membrane
  • h is the effective thickness of the membrane.
  • R is the molar gas constant
  • T is the absolute temperature
  • ⁇ is the apparent viscosity within the unstirred water layer or the lipophilic membrane
  • r is the radius of the permeating drag molecule
  • N is Avogadro's number.
  • D is the diffusion coefficient of the drug in the aqueous tear fluid
  • S is the total surface area of the solid drug particles
  • ho is the thickness of the diffusion layer at the particle surface
  • Cs is the saturation solubility of the drug in the aqueous fluid
  • C is the drug concentration in the bulk solution at time t.
  • the dissolution rate is proportional to both S and Cs, and Q is influenced by composition of the aqueous dissolution medium.
  • the pre-ocular solution volume remains constant, but drug concentration decreases due to dilution by tear turnover and corneal and non-corneal absorption.
  • the value of the first-order rate constant for the drainage of eye drops from precorneal area is typically about 1.5 min '1 in humans. Normal tear turnover is about 1.2 ⁇ l/min in humans (Sugrue 1989).
  • the precorneal half-life of topically applied drugs is between 1 and 3 minutes.
  • the water-soluble drug/cyclodextrin microparticles will not be washed away from the eye surface but adhere to the surface and the surrounding tissue.
  • the particles will dissolve rapidly enough to maintain the aqueous tear fluid saturated with the drug, i.e. the Q ? in Eq. 1 will not decrease during drainage of the eye.
  • Particles of lipophilic drugs with limited solubility in water (i.e. low C s in Eq. 4), will dissolve very slowly in the aqueous tear fluid.
  • Conventional suspensions, even in micronized form, will not possess sufficient rapid dissolution rates (i.e. dM/dt in Eq. 4) to maintain drug saturation of the aqueous tear fluid.
  • Formulating the drug as more water-soluble drug/cyclodextrin complexes (i.e. high C s in Eq. 4) in a microparticle (i.e. with a large S in Eq. 4) will ensure rapid drug dissolution. This will maintain drug saturation of the aqueous tear fluid (i.e. high C A q in Eq. 1). Cyclodextrin complexation will not change the lipophilicity (i.e. K in Eq. 2) of the drug and thus the cyclodextrin complexation will not affect the intrinsic ability of the drug molecules to permeate the lipophilic membrane (i.e. cyclodextrin complexation will not change P in Eq. 1).
  • This novel formulation technology will not only enhance the flux (J) of drug into the eye but also reduce the amount of drug reaching the systemic circulation via, for example, nasal absorption.
  • This novel ophthalmic (or nasal) formulation will enhance topical drug delivery into the eye, i.e. enhance ophthalmic (or nasal) drug availability and at the same time reduce the relative amount of drug reaching the systemic circulation (i.e. reduce systemic drug availability). The result is targeted drug delivery to the eye (or to the nasal mucosa).
  • microparticles will then consist of drug/ ⁇ -cyclodextrin, drug/ ⁇ -cyclodextrin or drug/ ⁇ -cyclodextrin complexes.
  • Such complexes are more water-soluble than the lipophilic drugs but less soluble than corresponding drug complexes of the cyclodextrin derivatives, such as drug complexes of 2- hydroxypropyl- ⁇ -cyclodextrin, 2-hydroxypropyl- ⁇ -cyclodextrin, randomly methylated ⁇ -cyclodextrin and sulfobutylether ⁇ -cyclodextrin.
  • drug complexes of 2- hydroxypropyl- ⁇ -cyclodextrin, 2-hydroxypropyl- ⁇ -cyclodextrin, randomly methylated ⁇ -cyclodextrin and sulfobutylether ⁇ -cyclodextrin are used to form aqueous eye drop solutions of lipophilic drugs.
  • small amounts of these very water-soluble cyclodextrin derivatives are included in the aqueous media containing the solid drug/cyclodextrin particles in order to increase further the concentration of dissolved drug (i.e. high C A q in Eq. 1) in the aqueous tear fluid.
  • small amounts of these very water-soluble cyclodextrin derivatives are present in the solid particles to enhance further the drug dissolution (i.e. to increase Cs and consequently dM/dt in Eq. 4).
  • the diffusion coefficient (D) of a permeating molecule is related to their size (i.e. their radius (r) in Eq. 3).
  • the cyclodextrin molecules are large (i.e. have a large r) and hydrophilic (i.e. have a small K in Eq. 2) and, thus, do not easily permeate biological membranes such as corneal and sclera. Thus, the dissolved cyclodextrin molecules will not permeate into the eye, only the smaller lipophilic drug molecules.
  • micro- and nano-systems consisting of cyclodextrins, drugs and various excipients, which due to their size and/or surface charge, possess mucoadhesive properties that results in enhanced drug absorption into the eye.
  • Typical eye drop formulation will consist of an aqueous drug suspension containing solid drug/cyclodextrin complexes, water-soluble polymers (such as hydroxypropyl methylcellulose, and other cellulose derivatives, and polyvinylpyrrolidone), metal ions (such as magnesium ions) and/or organic salts (such as sodium acetate and sodium citrate), where such additives are used to stabilize the system and lend it enhanced mucoadhesive properties.
  • water-soluble polymers such as hydroxypropyl methylcellulose, and other cellulose derivatives, and polyvinylpyrrolidone
  • metal ions such as magnesium ions
  • organic salts such as sodium acetate and sodium citrate
  • Drug refers to a pharmacologically active/useful ingredient whose solubility in water is less than 20 mg/ml, typically less than 1 mg/ml at physiologic pH.
  • Suitable drugs include those noted hereinabove, particularly corticosteroids such as dexamethasone, hydrocortisone, acecortane acetate, prednisolone, triamcinolone, fmorometholone, medrysone, rimexolone, loteprednol etabonate, etiprednol dicloacetate and triamcinolone acetonide; other steroids such as pregnanolone, testosterone and estradiol; carbonic anhydrase inhibitors like acetazolamide, dorzolamide, methazolamide, ethoxyzolamide and brinzolamide; antimicrobial agents such as trimethoprim and ciprofloxacin; GABAergic drugs
  • Table 1 Disorders affecting the posterior segment of the eye.
  • additional suitable drugs include growth factor inhibitors, such as pegaptanib (Macugen®), a vascular endothelial growth factor antagonist oligonucleotide, bevocizumab (Avastin®), an angiogenesis inhibitor, ranibizumab (Lucentis®), a humanized anti-vascular endothelial growth factor (VEGF) antibody fragment and AG013958, a growth factor inhibitor undergoing clinical trials for wet ADM; and antiproliferative cancer drugs, for example, daunorubicin, mitomycin C and 5- fluorouracil, which can prevent or inhibit scar tissue formation, for example, after glaucoma surgery; as well as drugs for the treatment of glaucoma, such as beta- blockers, for example timolol and betaxolol.
  • growth factor inhibitors such as pegaptanib (Macugen®), a vascular endothelial growth factor antagonist oligonucleotide, bevocizumab (Avastin®
  • antibiotics include antibiotics and antiviral agents.
  • additional useful drugs include anti-migraine drugs, for example, pizotifen, clonidine or sumatriptan; and narcotic analgesics, for example fentanyl or morphine.
  • the amount of drug used will be an amount effective to treat the condition for which the drug is administered, for example, in the case of an anti-inflammatory steroid or NSAID (non-steroidal anti-inflammatory drug), an anti-inflammatory effective amount; in the case of a carbonic anhydrase inhibitor, a carbonic anhydrase inhibitory effective amount; in the case of an anti-glaucoma agent, an anti-glaucoma effective amount; in the case of a drug administered to inhibit scar tissue, an effective scar tissue-inhibiting amount; in the case of a growth factor inhibitor, an effective growth antagonizing amount, and so forth.
  • an anti-inflammatory steroid or NSAID non-steroidal anti-inflammatory drug
  • Cyclodextrin as employed herein is usually from about 0.25 to about 40% (w/v), typically from about 2 to about 20 or about 25% (w/v).
  • Suitable cyclodextrins are the natural cyclodextrins, ⁇ -, ⁇ - and ⁇ -cyclodextrin; included as well may be their pharmaceutically acceptable derivatives such as the hydroxyalkyl derivatives of ⁇ -, ⁇ - and ⁇ -cyclodextrin (especially the hydroxyethyl and hydroxypropyl derivatives of ⁇ -cyclodextrin and ⁇ -cyclodextrin), randomly methylated ⁇ -cyclodextrin, sulfobutyl ether ⁇ -cyclodextrin, sulfobutyl ether ⁇ - cyclodextrin, and the so-called branched ⁇ - and ⁇ -cyclodextrin derivatives such as glucosyl- ⁇ -cyclodextrin and
  • the natural cyclodextrins are either used alone or in a mixture of two or more; by way of non-limiting example, a mixture of the natural ⁇ -cyclodextrin and the more water-soluble hydroxypropyl ⁇ - cyclodextrin, or ⁇ -cyclodextrin and sulfobutyl ether ⁇ -cyclodextrin, or ⁇ - cyclodextrin and hydroxypropyl- ⁇ -cyclodextrin or ⁇ -cyclodextrin and sulfobutyl ether ⁇ -cyclodextrin.
  • the relative amount of dissolved drug in the aqueous eye suspensions can be adjusted by using mixtures of cyclodextrins which have somewhat limited solubility in water and more water-soluble cyclodextrins.
  • the cyclodextrins are both used as solubilizers and to obtain sustained drug delivery after topical administration.
  • Water-soluble polymer as used herein is usually from 0 to about 5% (w/v), typically from about 0.1 to about 1% (w/v).
  • Suitable polymers are, for example, methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycol, poly(methyl methacrylate), polycarbophil, gelatin, alginate, poly(acrylic acid), polyethylene oxide and chitosan or a derivative of one of the foregoing.
  • the purpose of the polymers are, for example, to stabilize the nano- and microparticles in the aqueous environment, to enhanced the drug complexation efficiency, to increase the viscosity of the aqueous formulation, to obtain or enhance mucoadhesion, and to enhance sustainability of the drug delivery into the eye.
  • the gel formulations of the invention will contain larger amounts of polymers of this type.
  • Metal ions, or metal salts as used herein are usually from 0 to about 5% (w/v), typically from 0 to about 2% (w/v). Suitable metal ions are divalent magnesium cations (for example, in the form OfMgCl 2 -OH 2 O) and other di- and trivalent cations such as calcium, copper and iron.
  • the metal ions form complexes with various drugs as well as with cyclodextrins.
  • the metal ions/salts are used, for example, to solubilize cyclodextrins, drugs and drag/cyclodextrin complexes, to render surface charge to the nano- and microparticles, and to stabilize the particles.
  • Organic salts as used herein are usually from 0 to about 5% (w/v), typically from 0 to about 3% (w/v). Suitable organic salts are, for example, sodium or potassium salts of acetic acid, glutaric acid, tartaric acid, lactic acid, ascorbic acid and citric acid, as well as amino acids such as lysine.
  • the salts are, for example, used to enhance the cyclodextrin solubilization of drugs, to stabilize the particles and to ⁇ render surface charge to the nano- and micro-particles.
  • the following general guidance can be given:
  • These generally comprise from about 0.5 to about 20% (w/v) of solid particles dispersed in a vehicle containing from about 80 to about 99.5% (w/v) water. Viscosity is below 50 centiPoise, typically between 2 to 15 centiPoise.
  • such formulations comprise from about 20 to about 50% (w/v) of solid particles dispersed in a vehicle containing from about 50 to about 80% (w/v) water.
  • Solid particles Solid particle powder in general contains less than about 20% (w/v) water, typically less than about 7% (w/v) water. Cyclodextrins and cyclodextrin complexes are hygroscopic and thus the solid particles will easily absorb small amount of water from the environment. When stored in the lab in an open container, cyclodextrins contain from between about 5 and to about 10% (w/v) water. Insofar as concerns particle size, previous cyclodextrin eye drop formulations were clear transparent aqueous solutions. The present invention provides non-transparent suspensions or suspensions that are clearly not fully transparent.
  • particles in ophthalmic suspensions should be less than 10 ⁇ m in diameter to minimize irritation to the eye (Remington. The Science and Practice of Pharmacy, 21 st Ed., Lippincott Williams & Winkins, Philadelphia 2006, p. 856).
  • the particle size is up to 100 ⁇ m but the particles cause insignificant irritation since they dissolve relatively rapidly in the aqueous tear fluid. Further information relating to particle size is shown in Experiment 5 hereinbelow.
  • the compositions may further comprise at least one buffer salt and/or at least one preservative.
  • the eye drops, eye mist or eye gel that is, the ophthalmic composition, is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1 to about 90%, typically about 5 to about 50%, of the drug in solution, as free drug and dissolved drug/cyclodextrin complex(es), and from about 10 to about 99.9%, typically about 50 to about 95%, of the drug as solid drug/cyclodextrin particles.
  • the amount of dissolved drug can be controlled by the ratio of natural cyclodextrin and its water- soluble derivative in the formulation.
  • the size of the particles in the solid phase is from about 10 nm to about 1 mm, typically from about 0.1 to about 500 ⁇ m.
  • the drug/cyclodextrin particles are capable of dissolving in the aqueous tear fluid, generally within 24 hours, typically within 10 to 600 minutes, of administration to the eye surface. The particles will be retained on the eye surface and their dissolution will ensure constant high concentration of dissolved drug in the aqueous tear fluid. The resulting high thermodynamic activity of the drug in the tear fluid will enhance drug permeation into the eye. Also, since administration of the cyclodextrin delivery system will result in sustained high drug concentration in the tear fluid, the amount of drug absorbed after each administration will be enhanced.
  • Table 6 shows that the site-specificity of the aqueous drug/cyclodextrin eye drop suspension is significantly greater that that of an aqueous drug/cyclodextrin eye drop solution.
  • Experiment 5 relates to microscopic studies of particle size.
  • Experiment 6 shows solubilizing effects of cyclodextrins on some drugs.
  • the two most common causes of blindness in developed countries are age- related macular degeneration and diabetic retinopathy.
  • age-related macular degeneration are diseases of the retina and the posterior segment of the eye.
  • Old drugs such as corticosteroids (e.g. triamcinolone and dexamethasone) and new drugs, such as drugs directed against vascular endothelial growth factors and others, show promise in dealing with these diseases but their delivery is very difficult.
  • Traditional eye drops are inadequate in delivering drugs to the posterior segment of the eye. Intravitreal injections are commonly used today.
  • Aqueous isotonic solution contained 0.5% [l,2,4,6,7- 3 H]-dexamethasone, 5.3% randomly methylated ⁇ -cyclodextrin DS 1.8, benzalkonium chloride (0.02%), EDTA (0.10%), hydroxypropyl methylcellulose (0.10% w/v) and sodium chloride (0.72%), all w/v %.
  • This solution 50 ⁇ l was administered to three groups of rabbits (3x6 rabbits) as eye drops to the left eye only, as nasal spray and as intravenous injection. Blood samples were collected every 30 minutes after drug administration and the rabbits sacrificed after 2 hours.
  • H&E Hematoxylin-eosin
  • Experiment 3 The purpose of this study was to investigate the concentration of dexamethasone in various eye tissues after topical administration of 0.5 and 1.5% (w/v) dexamethasone solutions containing randomly methylated ⁇ -cyclodextrin as solubilizer.
  • Benzalkonium chloride was purchased from Sigma (USA). Soluene ® -350 solubilizer, and liquid scintillation cocktails Hionic FluorTM and Ultima GoldTM were purchased from Perkin Elmer (UK). All other chemicals used in this study were commercially available compounds of special reagent or analytical grade. Solubility studies: Phase-solubility study was performed to determine the exact amount of RM ⁇ CD needed to solubilize dexamethasone in the eye drop medium.
  • dexamethasone was added to aqueous solution containing from 0 to 25% (w/v) RM ⁇ CD, benzalkonium chloride (0.02% w/v), EDTA (0.1% w/v), NaCl (0.00 to 0.72% w/v) and HPMC (0.1%).
  • the suspensions formed were heated in an autoclave (Midmark M7 SpeedClave) in sealed containers to 121 °C for 20 min. The suspensions were allowed to cool to room temperature (22-23°C) and equilibrate for 7 days. After equilibrium was attained, the suspension was filtered through a 0.45 ⁇ m membrane filter, diluted and analyzed by HPLC.
  • phase-solubility diagram of dexamethasone was determined in the aqueous RM ⁇ CD (0-25% w/v) eye drop solutions.
  • the phase-solubility was determined to be of AL- type and thus dexamethasone appears to form 1 : 1 dexamethasone/RM ⁇ CD complex in the aqueous eye drop formulation.
  • Aqueous 0.5 and 1.5% (w/v) dexamethasone eye drop solution was prepared by dissolving 250 or 750 mg of dexamethasone in 45 ml of aqueous solution containing benzalkonium chloride (10 mg), EDTA (50 mg), HPMC (50 mg), NaCl (0 or 360 mg) and RM ⁇ CD (2.65 or 9.0 g) and then filled up to 50 ml.
  • the solution was heated in an autoclave (Midmark M7 SpeedClave) in sealed containers to 121°C for 20 min. The solution was allowed to cool to room temperature (22-23°C) and equilibrate for 7 days.
  • RM ⁇ CD aqueous eye drop formulation
  • the osmolarity of the solutions was measured by the freezing point depression method using a Knauer Osmometer Automatic (Netherlands).
  • the viscosity was determined by a Brookfield digital viscometer model DV-1+ (U.S.A.) operated at room temperature.
  • the osmolarity of the eye drops was determined to be 284 m ⁇ sm/kg.
  • the viscosity was about 2.5 cps.
  • Dosing solution (labeled): The required volume of radioactive dexamethasone ethanolic solution was pipetted in a vial and as much as possible of the ethanol allowed to evaporate almost to dryness without precipitating the dexamethasone. Then, a required amount of dexamethasone eye drop solution was added and that solution was shaken for at least 2 hours.
  • Aqueous humor 10 ml of Ultima gold was added to aqueous humor samples (about 0.2g), the vials were stoppered, shaken and kept in the dark for at least 12 hours prior to counting in a liquid scintillation counter
  • Blood samples Blood samples were prepared by adding 1 ml mixture of Soluene ® -350:isopropanol to 0.1-0.2 ml of the blood and incubated at 50°C for 60 minutes. The vials were then allowed to cool down to room temperature and 0.5 ml of 30% hydrogen peroxide solution was then added dropwise with swirling to each vial for decolorization. The solutions were allowed to stand at room temperature for 10 minutes.
  • tissue samples were handled in the same way as the blood samples except that 0.5-2.0 ml of Soluene - 350 was added to the samples depending on the size of the tissue sample. No isopropanol or hydrogen peroxide was used and the samples were incubated for 240 minutes at 50°C before adding the Hionic FluorTM (5-20 ml depending on sample size).
  • Dexamethasone was detected in all blood samples and in all tissue samples from the eyes after all three different routes of administration. Blank tissue samples were spiked with various amounts of labeled dexamethasone from the dosing solution and used as a standard.
  • Table 3 lists the concentration of dexamethasone after topical application of 0.5% dexamethasone in the left (study) eye and the right (control eye) as well as after intravenous or intranasal application of the same drug dose.
  • Increasing the drug concentration in the eye drop solution from 0.5% to 1.5% resulted in over two-fold increase in drug concentration in the posterior segment of the eye, and three to four fold increase in both aqueous humor and iris ciliary body.
  • FIG. 1 shows the concentration of dexamethasone in blood. While the pharmacokinetics is different among the topical, intravenous and intranasal application, the concentration of dexamethasone in blood is similar 2 hours after application.
  • FIG. 2 shows the percentage of the drug concentration in each tissue that is delivered by topical absorption or by systemic absorption.
  • topical absorption dominates in the anterior part of the eye.
  • Topical absorption is also important for drug delivery to the posterior segment and is responsible for more than half of the drug levels in the vitreous and retina following eye drop application in our model.
  • Systemic absorption accounts for about 40% of the drug reaching the posterior part of the eye in this model and topical absorption accounts for 60%.
  • the drag levels may be further increased by raising the concentration to 1.5% dexamethasone and more frequent application and may present a potential drag delivery platform for treatment of retinal diseases with steroids and other drags, through a noninvasive route.
  • the increased drag levels in the posterior segment of the eye is mainly due to increased delivery via the systemic route (from the nasal cavity).
  • Iris-Ciliary body 548 ⁇ 290 43 ⁇ 36 136 ⁇ 42 19 ⁇ 7 15 ⁇ 4 19 ⁇ 6 19 ⁇ 5 19 ⁇ 6 Lens 19 ⁇ 9 5 ⁇ 3 11 ⁇ 3 2 ⁇ 0 3 ⁇ 1 3 ⁇ 1 3 ⁇ 1 3 ⁇ 1 -4
  • a representative drug was chosen to illustrate the improved site-specificity of an aqueous cyclodextrin drug suspension as compared to an aqueous cyclodextrin drug solution in targeting delivery to the vitreous, retina and optic nerve following administration to the eye surface.
  • the purpose of this study was to investigate the concentration of dexamethasone in various eye tissues after topical administration of a dexamethasone suspension containing ⁇ -cyclodextrin.
  • Solubility studies Phase-solubility study was performed to determine the exact amount of ⁇ CD needed to solubilize dexamethasone. An excess amount of dexamethasone was added to aqueous solution or suspension containing from 0 to 10% (w/v) ⁇ CD. The dexamethasone suspensions formed were heated in an autoclave (Midmark M7 SpeedClave) in sealed containers to 121 0 C for 20 min. The suspensions were allowed to cool to room temperature (22-23 0 C) and equilibrate for 7 days. After equilibrium was attained, the suspension was filtered through a 0.45 ⁇ m membrane filter, and the filtrate diluted and analyzed by HPLC.
  • the phase- solubility diagram in pure water was determined to be of Bs-type with a maximum dexamethasone solubility of 5.3 mg/ml at 5% (w/v) ⁇ CD concentration.
  • Formulation of the eye drops a) Cold suspension: Aqueous 1.5% (w/v) dexamethasone eye drop suspension was prepared by suspending 750 mg of dexamethasone in 50 ml of aqueous solution containing benzalkonium chloride (10 mg), EDTA (50 mg), HPMC (50 mg), NaCl (100 mg) and ⁇ CD (9.0 g). The suspension was heated in an autoclave (Midmark M7 SpeedClave) in sealed containers to 121°C for 20 min.
  • the suspension was allowed to cool to room temperature (22-23°C) and equilibrate for 7 days.
  • the osmolarity of the solutions was measured by the freezing point depression method using a Knauer Osmometer Automatic (Netherlands).
  • the viscosity was determined by a Brookfield digital viscometer model DV-1+ (U.S.A.) operated at room temperature.
  • the osmolarity of the eye drop suspension was determined to be about 300 m ⁇ sm/kg (or milliosmolality/kg).
  • the viscosity was about 2.3 cps.
  • the amount of dissolved dexamethasone in the aqueous eye drop suspension was determined to be between 0.7 and 0.9 mg/ml or only about 5% of the total amount of dexamethasone in the eye drop formulation, b) Dosing suspension (labeled): The required volume of radioactive dexamethasone ethanolic solution was pipetted in a vial and as much as possible of the ethanol allowed to evaporate almost to dryness without precipitating the dexamethasone. Then, a required amount of dexamethasone eye drop suspension was added and that solution was sonicated for 30 minutes and shaken at room temperature for at least 24 hours. In vivo studies: Eight young, unanaesthetized female albino rabbits (HB
  • sample preparation The aqueous humor was removed from the eye using 1 ml syringe attached to a 26-gauge needle and placed in a polyethylene (scintillation) vial. One lateral incision was performed in the sclera (center of the eyeball) and the eye was totally opened (anterior part and posterior part).
  • the lens and the iris-ciliary body were removed and the cornea was separated from the remaining anterior sclera.
  • the vitreous humor was emptied into a vial.
  • the retina was gently scraped away and the optic nerve (about 2 mm) was cut off. While dissecting the eyes, all the samples were immediately put in dry scintillation vials and weighed. Great care was taken to prevent cross-contamination between individual tissue samples and eye fluids. The entire procedure took less than 15 minutes per eye so that any errors due to redistribution of drug were minimized.
  • Aqueous humor 10 ml of Ultima gold was added to aqueous humor samples (about 0.2 g), the vials were stoppered, shaken and kept in the dark for at least 12 hours prior to counting in a liquid scintillation counter
  • Blood samples Blood samples were prepared by adding 1 ml mixture of Soluene ® -350:iso ⁇ ronanol to 0.1-0.2 ml of the blood and incubated at 50°C for 60 minutes. The vials were then allowed to cool down to room temperature and 0.5 ml of 30% hydrogen peroxide solution was then added dropwise with swirling to each vial for decolorization.
  • the amount of dissolved dexamethasone in the aqueous eye drop suspension was between 0.7 and 0.9 mg/ml, or only about 5% of the total amount of dexamethasone in the eye drop formulation, the dexamethasone amount in the various tissues is comparable or even higher than after administration of the same amount (i.e. 1.5% dexamethasone RM ⁇ CD solution) as shown in Table 5. Furthermore, the administration of the dexamethasone/ ⁇ -cyclodextrin suspension increases the relative amount of drug reaching the posterior segment of the eye via the topical route and decreases the dexamethasone concentration in blood (FIGs. 3 and 4).
  • no particles were observed under the same conditions in the dexamethasone/RM ⁇ CD eye drop solutions.
  • phase-solubilities of drugs in aqueous solutions containing the natural ⁇ -, ⁇ - or ⁇ -cyclodextrins are, in general, of B s -type, meaning that the drug/cyclodextrin complex has limited solubility in water.
  • concentrations above the solubility of the drug/cyclodextrin complex only a fraction of the drug will be in solution as drug/cyclodextrin complex and a fraction of the drug will be present as drug/cyclodextrin solid particles in suspension.
  • All three natural cyclodextrins that is ⁇ -, ⁇ - and ⁇ -cyclodextrin, form B s -type phase-solubility diagrams while the more water-soluble cyclodextrin derivatives, such as 2-hydroxypropyl- ⁇ -cyclodextrin and sulfobutyl ether ⁇ -cyclodextrin, do in general form water-soluble complexes or complexes that have much greater water-solubility than complexes of the same drugs with ⁇ -, ⁇ - and ⁇ -cyclodextrin.
  • FIG. 7 shows the phase-solubility of hydrocortisone in water containing the natural ⁇ -cyclodextrin.
  • the maximum hydrocortisone solubility obtained is 2.2 mg/ml and it will not increase with increasing amount of cyclodextrin. On the contrary it will, at certain cyclodextrin concentration, decrease with increasing amount of ⁇ -cyclodextrin (which is characteristic for phase-solubility profiles of B s -type).
  • the maximum solubility was determined to be 5.3 mg/ml.
  • the solubility of dexamethasone in aqueous eye drop formulation containing 18% ⁇ -cyclodextrin was determined to be 0.7 to 0.9 mg/ml (see EXPERIMENT 4).
  • the aqueous complexation media for hydrocortisone is a solution at ⁇ -cyclodextrin concentrations below about 1.8% but a suspension at higher ⁇ -cyclodextrin concentrations.
  • AGOl 3958 (VEGFR/PDGFR inhibitor): ⁇ -cyclodextrin: 0.01 mg/ml (7.5%), 0.02 mg/ml (15%).
  • Cyclosporine A (immunosuppressant): ⁇ -cyclodextrin: 0.2 mg/ml (5%), 0.9 mg/ml (10%).
  • 2-Hydroxypropyl- ⁇ -cyclodextrin 0.5 mg/ml (15%)
  • 2-Hydroxypropyl- ⁇ -cyclodextrin 0.2 mg/ml (10%)
  • Dexamethasone (corticosteroid): ⁇ -cyclodextrin: 3 mg/ml (5%) Randomly methylated ⁇ -cyclodextrin: 5 mg/ml (5%)
  • 2-Hydroxypropyl- ⁇ -cyclodextrin 4 mg/ml (5%)
  • the drugs will form drug/cyclodextrin suspensions in the aqueous eye drop formulations.
  • the suspensions will partly dissolve upon topical administration to the eye forming a saturated drug solution in the aqueous tear fluid, maximizing the amount of drug partitioning into cornea, slera and other surface tissues.
  • the high chemical potential of the drug in a saturated solution will increase the chemical potential gradient which is the driving force of passive diffusion.
  • Drug solubility in the aqueous eye drop formulation and/or the tear fluid can be adjusted by simultaneous usage of a natural cyclodextrin and a more water- soluble cyclodextrin derivative.
  • a human study is planned to find the level of dexamethasone delivered to the back of the human eye by an eye drop suspension containing dexamethasone- cyclodextrin particles prepared in accord with the invention.
  • Patients who are planning to undergo vitreous surgery will be recruited for the study by informed consent. They will receive one drop of the eye drop suspension at 1, 2 and 4 hours prior to surgery. During surgery, a small sample of the vitreous gel (which is removed routinely in vitreous surgery) will be obtained and stored for dexamethasone measurement.
  • An ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about
  • composition according to embodiment 1 in the form of eye drops.
  • composition according to embodiment 1 in the form of an eye mist or an eye gel. 4.
  • the composition according to embodiment 1, 2 or 3, comprising from about 0.25% to about 40% of cyclodextrin.
  • composition according to embodiment 4 comprising from about 2% (w/v) to about 20% (w/v) of cyclodextrin.
  • composition according to any one of the preceding embodiments further comprising up to about 5% (w/v) of water-soluble polymer.
  • composition according to embodiment 6, comprising from about 0.1% (w/v) to about 1% (w/v) of water-soluble polymer.
  • composition according to any one of the preceding embodiments further comprising up to about 5% (w/v) of metal salts.
  • composition according to embodiment 8 comprising up to about 2% (w/v) of metal salts.
  • composition according to any one of the preceding embodiments further comprising up to about 5% (w/v) of organic salts.
  • composition according to embodiment 10 comprising up to about 3% (w/v) of organic salts.
  • composition according to any one of the preceding embodiments further comprising at least one buffer salt and/or at least one preservative.
  • composition according to any one of the preceding embodiments wherein the aqueous phase comprises from about 5% (w/v) to about 50% (w/v) of the drug in solution, as free drug and dissolved drug/cyclodextrin complex(es), and from about 50% (w/v) to about 95% (w/v) of the drug as solid drug/cyclodextrin particles.
  • the size of the particles in the solid phase is from about 0.1 ⁇ m to about 500 ⁇ m.
  • composition according to any one of embodiments 1-15 comprising at least one pharmaceutically acceptable derivative of ⁇ -, ⁇ - or ⁇ -cyclodextrin.
  • composition according to embodiment 17, wherein the at least one pharmaceutically acceptable derivative is selected from the group consisting of hydroxyalkyl- ⁇ -cyclodextrins, hydroxyalkyl- ⁇ -cyclodextrins, randomly methylated ⁇ -cyclodextrin, ⁇ -cyclodextrin sulfobutyl ether, ⁇ -cyclodextrin sulfobutyl ether, branched ⁇ -cyclodextrins and branched ⁇ -cyclodextrins.
  • composition according to embodiment 18, wherein the at least one pharmaceutically acceptable derivative is hydroxypropyl- ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, randomly methylated ⁇ -cyclodextrin, ⁇ -cyclodextrin sulfobutyl ether, ⁇ -cyclodextrin sulfobutyl ether or glucosyl- ⁇ -cyclodextrin.
  • composition according to embodiment 16 wherein the cyclodextrin comprises at least ⁇ -cyclodextrin.
  • composition according to embodiment 17 wherein the cyclodextrin comprises at least hydroxypropyl- ⁇ -cyclodextrin. 22. The composition according to embodiment 6, wherein said polymer is a cellulose derivative.
  • composition according to embodiment 6, wherein said polymer is methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, carboxymethylcellulose, polyvinyl alcohol, poly(methyl methacrylate), polycarbophil, gelatin, alginate, poly(acrylic acid), polyvinylpyrrolidone, polyethylene glycol, polyethylene oxide or chitosan, or a derivative of one of the foregoing.
  • composition according to embodiment 8, wherein said metal salt has a divalent or trivalent cation wherein said metal salt has a divalent or trivalent cation.
  • composition according to embodiment 26, wherein said magnesium salt is magnesium chloride.
  • composition according to embodiment 10, wherein said organic salt is a salt of or the ionized form of acetic acid, glutaric acid, a hydroxy acid or an amino acid.
  • composition according to embodiment 28, wherein said organic salt is a salt of or the ionized form of citric acid, lactic acid, ascorbic acid, tartaric acid or lysine.
  • composition according to embodiment 1, wherein said drug is a carbonic anhydrase inhibitor.
  • said carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxyzolamide or brinzolamide.
  • composition according to embodiment 1, wherein said drug is a steroid is a steroid.
  • composition according to embodiment 32, wherein said steroid is dexamethasone, hydrocortisone, triamcinolone, triamcinolone acetonide, prednisolone, fluorometholone, medrysone, rimexolone, pregnanolone, loteprednol etabonate or etiprednol dicloacetate.
  • composition according to embodiment 34 wherein said GABAergic drug is baclofen, tiagabine, valproic acid, progabide, muscimol, etomidate or propofol.
  • GABAergic drug is a benzodiazepine.
  • composition according to embodiment 36, wherein the benzodiazepine is diazepam, alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, nitrazepam, oxazepam, medazepam, lorazepam, prazepam, quazepam, triazolam, warmthzepam or lorazolam.
  • composition according to embodiment 1, wherein said drug is a non-steroidal antiinflammatory drug.
  • composition according to embodiment 38 wherein the non- steroidal anti-inflammatory drug is naproxen or ketoprofen. 40. The composition according to embodiment 1, wherein said drug is an antibiotic.
  • composition according to embodiment 1 wherein said drug is an antiviral agent.
  • composition according to embodiment 1, wherein said drug is cyclosporin A.
  • composition according to embodiment 43, wherein the prostaglandin is latanoprost.
  • a nasal composition which is an aqueous suspension comprising drug;, cyclodextrin and water, the composition having an aqueous phase of from about 1% (w/v) to about 95% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 5% (w/v) to about 99% (w/v) of the drug as solid drug/cyclodextrin particles, the size of the particles in the solid phase being from about 10 run to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in nasal mucus fluid within about 24 hours after application to the nasal mucosa.
  • composition according to embodiment 45 in the form of nose drops.
  • composition according to embodiment 45 in the form of a nasal mist or a nasal gel.
  • composition according to embodiment 45, 46 or 47 comprising from about 0.25% to about 45% of cyclodextrin.
  • composition according to embodiment 48 comprising from about 2% (w/v) to about 25% (w/v) of cyclodextrin. 50.
  • composition according to embodiment 50 comprising from about 0.1% (w/v) to about 1% (w/v) of water-soluble polymer.
  • composition according to embodiment 52 comprising up to about 2% (w/v) of metal salts.
  • composition according to embodiment 54 comprising up to about 3% (w/v) of organic salts.
  • composition according to any one of embodiments 45-55 further comprising at least one buffer salt and/or at least one preservative.
  • composition according to any one of embodiments 45-56, wherein the aqueous phase comprises from about 10% (w/v) to about 50% (w/v) of the drug in solution, as free drug and dissolved drug/cyclodextrin complex(es), and from about 50% (w/v) to about 90% (w/v) of the drug as solid drug/cyclodextrin particles.
  • composition according to embodiment 60 further comprising at least one pharmaceutically acceptable derivative of ⁇ -, ⁇ - or ⁇ -cyclodextrin.
  • composition according to embodiment 61, wherein the at least one pharmaceutically acceptable derivative is selected from the group consisting of hydroxyalkyl- ⁇ -cyclodextrins, hydroxyalkyl- ⁇ -cyclodextrins, randomly methylated ⁇ -cyclodextrin, ⁇ -cyclodextrin sulfobutyl ether, ⁇ -cyclodextrin sulfobutyl ether, branched ⁇ -cyclodextrins and branched ⁇ -cyclodextrins.
  • composition according to embodiment 62, wherein the at least one pharmaceutically acceptable derivative is hydroxypropyl- ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, randomly methylated ⁇ -cyclodextrin, ⁇ -cyclodextrin sulfobutyl ether, ⁇ -cyclodextrin sulfobutyl ether or glucosyl- ⁇ -cyclodextrin.
  • composition according to embodiment 60, wherein the cyclodextrin comprises at least ⁇ -cyclodextrin.
  • composition according to embodiment 64, wherein the cyclodextrin comprises at least hydroxypropyl- ⁇ -cyclodextrin.
  • composition according to embodiment 50 wherein said polymer is a cellulose derivative.
  • said polymer is a mucoadhesive water-soluble polymer.
  • composition according to embodiment 50 wherein said polymer is methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, carboxymethylcellulose, polyvinyl alcohol, poly(methyl methacrylate), polycarbophil, gelatin, alginate, poly(acrylic acid), polyvinylpyrrolidone, polyethylene glycol, polyethylene oxide or chitosan, or a derivative of one of the foregoing.
  • composition according to embodiment 70, wherein said magnesium salt is magnesium chloride.
  • composition according to embodiment 54 wherein said organic salt is a salt of or the ionized form of acetic acid, glutaric acid, a hydroxy acid or an amino acid.
  • composition according to embodiment 72, wherein said organic salt is a salt of or the ionized form of citric acid, lactic acid, ascorbic acid, tartaric acid or lysine.
  • composition according to embodiment 45 wherein said drug is a steroid.
  • composition according to embodiment 74, wherein said steroid is dexamethasone, hydrocortisone, triamcinolone, triamcinolone acetonide, prednisolone, fluorometholone, medrysone, rimexolone, pregnanolone, loteprednol etabonate or etiprednol dicloacetate.
  • composition according to embodiment 45 wherein said drug is an anti-migraine drug.
  • composition according to embodiment 76 wherein said antimigraine drug is pizotifen, clonidine or sumatriptan.
  • composition according to embodiment 45 wherein said drug is a narcotic analgesic.
  • composition according to embodiment 78, wherein said narcotic analgesic is fentanyl or morphine.
  • composition according to embodiment 45 wherein said drug is propofol, ketamine, scopolamine, etomidate, nicotine, estradiol or testosterone.
  • composition according to embodiment 45 wherein said drug is a GABAergic drug.
  • composition according to embodiment 81, wherein said GABAergic drug is a benzodiazepine is a benzodiazepine.
  • composition according to embodiment 82, wherein the benzodiazepine is diazepam, alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, nitrazepam, oxazepam, medazepam, lorazepam, prazepam, quazepam, triazolam, warmthzepam or lorazolam.
  • An ophthalmic composition which is a powder obtained by drying an aqueous suspension as defined in any one of embodiments 1 , and 4-44. 85. The composition according to embodiment 84, obtained by lyophilizing or spray-drying said aqueous suspension.
  • composition according to embodiment 1, wherein said cyclodextrin is a mixture of a natural ⁇ -, ⁇ - or ⁇ -cyclodextrin and the corresponding water-soluble ⁇ -, ⁇ - or ⁇ -cyclodextrin derivative.
  • composition according to embodiment 86 wherein said water- soluble derivative is selected from the group consisting of hydroxyalkyl- ⁇ - cyclodextrins, hydroxyalkyl- ⁇ -cyclodextrins, randomly methylated ⁇ -cyclodextrin, the sulfobutyl ether of ⁇ -cyclodextrin, the sulfobutyl ether of ⁇ -cyclodextrin, branched ⁇ -cyclodextrins and branched ⁇ -cyclodextrins.
  • composition according to embodiment 87 wherein said water- soluble derivative is selected from the group consisting of hydroxypropyl- ⁇ - cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, randomly methylated ⁇ -cyclodextrin, the sulfobutyl ether of ⁇ -cyclodextrin, the sulfobutyl ether of ⁇ -cyclodextrin, glucosyl ⁇ -cyclodextrin and glucosyl ⁇ -cyclodextrin.
  • composition according to embodiment 86, wherein said cyclodextrin is a mixture of ⁇ -cyclodextrin and 2-hydroxypropyl- ⁇ -cyclodextrin.
  • composition according to embodiment 86 wherein said cyclodextrin is a mixture of ⁇ -cyclodextrin and the sulfobutyl ether of ⁇ -cyclodextrin.
  • composition according to embodiment 86 wherein said cyclodextrin is a mixture of ⁇ -cyclodextrin and 2-hydroxypropyl- ⁇ -cyclodextrin.
  • cyclodextrin is a mixture of ⁇ -cyclodextrin and the sulfobutyl ether of ⁇ - cyclodextrin.
  • composition according to embodiment 86, wherein said cyclodextrin is a mixture of ⁇ -cyclodextrin and randomly methylated ⁇ -cyclodextrin.
  • a method for the treatment of a condition of the posterior segment and/or the anterior segment of the eye comprising applying topically to the eye surface of a subject in need of such treatment, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition according to embodiment 1.
  • composition according to embodiment 1, wherein the drug is
  • AGOl 3958 triamcinolone acetonide, ranibizumab, macugen or sham. 100.
  • the composition according to embodiment 99 in the form of eye drops.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/IB2006/002769 2005-07-22 2006-07-21 Cyclodextrin nanotechnology for ophthalmic drug delivery WO2007012974A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06808951.5A EP1909755B1 (en) 2005-07-22 2006-07-21 Cyclodextrin nanotechnology for ophthalmic drug delivery
PL06808951T PL1909755T3 (pl) 2005-07-22 2006-07-21 Nanotechnologia cyklodekstryn do dostarczania leku do oczu
ES06808951.5T ES2675043T3 (es) 2005-07-22 2006-07-21 Nanotecnología de ciclodextrina para administración de fármaco oftálmico

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70162105P 2005-07-22 2005-07-22
US60/701,621 2005-07-22
US79556306P 2006-04-28 2006-04-28
US60/795,563 2006-04-28

Publications (2)

Publication Number Publication Date
WO2007012974A2 true WO2007012974A2 (en) 2007-02-01
WO2007012974A3 WO2007012974A3 (en) 2007-07-12

Family

ID=37564167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002769 WO2007012974A2 (en) 2005-07-22 2006-07-21 Cyclodextrin nanotechnology for ophthalmic drug delivery

Country Status (5)

Country Link
US (4) US7893040B2 (en28)
EP (1) EP1909755B1 (en28)
ES (1) ES2675043T3 (en28)
PL (1) PL1909755T3 (en28)
WO (1) WO2007012974A2 (en28)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009079679A3 (de) * 2007-12-21 2009-11-26 Aop Orphan Pharmaceuticals Ag Pharmazeutische zusammensetzung zur parenteralen verabreichung eines ultrakurzwirksamξn beta-adrenorezeptor antagonisten
WO2010033528A1 (en) 2008-09-19 2010-03-25 Alcon Research, Ltd. Stabilized pharmaceutical sub-micron suspensions and methods of forming same
WO2011113904A1 (en) * 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
US9851351B2 (en) 2009-01-29 2017-12-26 Forsight Vision4, Inc. Posterior segment drug delivery
US9861521B2 (en) 2010-08-05 2018-01-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9895369B2 (en) 2014-08-08 2018-02-20 Forsight Vision4, Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
RU2672596C2 (ru) * 2012-01-23 2018-11-16 Аллерган, Инк. Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2019043169A1 (en) * 2017-09-01 2019-03-07 Murray & Poole Enterprises, Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
US10398593B2 (en) 2013-03-28 2019-09-03 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
EP4194011A1 (en) * 2016-11-29 2023-06-14 Oculis SA Preparation of cyclodextrin nanoparticle for ophthalmic drug delivery
EP4121417A4 (en) * 2020-05-01 2023-08-09 University Of Southern California CYCLODEXTRIN-BASED ANTIMICROBIAL THERAPY
WO2023148231A1 (en) * 2022-02-02 2023-08-10 Oculis SA Multidose ophthalmic compositions
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US12186424B2 (en) 2015-06-06 2025-01-07 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium recurrence
WO2025082585A1 (en) 2023-10-16 2025-04-24 Oculis Operations Sàrl Method of treating diabetic macular edema
WO2025083031A1 (en) 2023-10-16 2025-04-24 Oculis Operations Sàrl Method of treating diabetic macular edema
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
AU2005290583A1 (en) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. Fine particles-containing composition and manufacturing method therefor
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
AU2008310956B2 (en) * 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
TWI468165B (zh) * 2008-03-11 2015-01-11 Alcon Res Ltd 用於玻璃體內注射之低黏性高度絮凝之丙酮特安皮質醇懸浮液
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US20100105643A1 (en) * 2008-10-27 2010-04-29 Soll David B Ophthalmic composition
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
WO2010144194A1 (en) * 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
CA2748765C (en) 2009-07-06 2014-07-22 Akebia Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
ES2351756B1 (es) 2009-07-28 2011-10-05 Universidad Del Pais Vasco Nanopartículas lipídicas para terapia génica.
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
CN103052387A (zh) * 2010-07-22 2013-04-17 德国麦氏大药厂 含色氨酸衍生物的药物组合物
CA2807554C (en) 2010-08-05 2021-10-26 Forsight Vision4 Inc. Implantable therapeutic device
CN103209683B (zh) * 2010-08-17 2016-08-31 Ohr制药股份有限公司 角鲨胺的眼用制剂
ES2385080B1 (es) * 2010-12-21 2013-05-10 Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea Nanopartículas lipídicas para el tratamiento de enfermedades oculares.
CA2827336C (en) 2011-02-23 2016-01-26 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
HK1201178A1 (en) 2011-10-13 2015-08-28 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
JP6508944B2 (ja) 2012-02-15 2019-05-08 サイデックス・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン誘導体のための製造方法
EP3808339A1 (en) 2012-05-03 2021-04-21 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2871778C (en) 2012-05-03 2022-09-13 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
WO2014127018A1 (en) * 2013-02-12 2014-08-21 Ys Pharmtech Epinephrine formulations for medicinal products
HK1220698A1 (zh) * 2013-03-13 2017-05-12 Seattle Genetics, Inc. 環糊精和抗體藥物偶聯物製劑
CA2900840C (en) 2013-03-14 2023-03-28 Panoptica, Inc. Ocular formulations for drug-delivery to the posterior segment of the eye
EP3607821B1 (en) 2013-03-15 2022-08-03 EyePoint Pharmaceuticals, Inc. Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
FR3006315B1 (fr) * 2013-05-31 2015-10-02 Centre Nat Rech Scient Microparticules et nanoparticules auto-associatives composees de proteines
WO2015002893A1 (en) * 2013-07-02 2015-01-08 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
US9511341B2 (en) 2013-08-30 2016-12-06 Sunny Pharmtech Inc. Method for preparing acetazolamide sodium powder
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
WO2015175954A1 (en) * 2014-05-16 2015-11-19 Scifluor Life Sciences, Inc. Alpha v integrin antagonist compositions
US9694109B1 (en) * 2015-01-06 2017-07-04 Brahm Holdings, Llc Nanoparticle-containing placental constructs and methods of use
BR112017025631A2 (pt) * 2015-05-29 2018-08-07 Oculis Ehf composições oftálmicas aquosas, método de induzir ou aumentar a formação de lágrima, método de formação de aglomerados de ciclosporina a e uso de ciclosporina a
US20200297734A1 (en) 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10555952B2 (en) 2015-06-19 2020-02-11 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
ES2604816B1 (es) * 2015-09-09 2018-01-29 Farmalider, S.A. Composición farmacéutica de tramadol para uso oftálmico
US10952992B2 (en) 2015-09-23 2021-03-23 Aerpio Pharmaceuticals, Inc. Methods of treating intraocular pressure with activators of Tie-2
GB2556082A (en) * 2016-11-18 2018-05-23 Warneford Healthcare Ltd Ophthalmic composition
US20180177744A1 (en) * 2016-12-22 2018-06-28 Gary Jay Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
WO2018138621A1 (en) * 2017-01-27 2018-08-02 Innovative Nano & Micro Technologies Pvt Ltd (Inm Technologies) Acetazolamide ophthalmic solution
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
ES2914305T3 (es) * 2017-12-26 2022-06-09 Ind Tech Res Inst Composición para mejorar la solubilidad de sustancias poco solubles, uso de la misma y formulación compleja que contiene la misma
WO2019231858A1 (en) * 2018-06-01 2019-12-05 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US12343163B2 (en) 2018-08-09 2025-07-01 Michael Feeney Imaging system and method for enhanced visualization of near surface vascular structures
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
US10952981B2 (en) * 2019-05-27 2021-03-23 Slayback Pharma Llc Liquid pharmaceutical compositions of baclofen for oral administration
CN114040766A (zh) 2019-07-01 2022-02-11 奥库里斯公司 用于稳定包含药物的水性组合物pH的方法
HU231668B1 (hu) * 2021-12-28 2025-06-28 Semmelweis Egyetem 60% Szemcsepp készítmény
CN114558046B (zh) * 2022-01-30 2023-06-23 潍坊医学院附属医院 一种改善稳定性的眼科制剂及其制备方法
EP4356929A1 (en) 2022-10-19 2024-04-24 Universität Rostock Antifibrotic formulation for ophthalmic treatment
WO2024091659A1 (en) * 2022-10-28 2024-05-02 Aldeyra Therapeutics, Inc. Modified cyclodextrins and ophthalmic uses thereof
WO2024239072A1 (en) * 2023-05-25 2024-11-28 The University Of Melbourne Iontophoresis pharmaceutical delivery system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
EP0709099A3 (en) 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
US20070065492A1 (en) 2003-03-28 2007-03-22 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008340179B2 (en) * 2007-12-21 2014-10-23 Aop Orphan Pharmaceuticals Gmbh Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
US11517624B2 (en) 2007-12-21 2022-12-06 Aop Orphan Pharmaceuticals Gmbh Pharmaceutical composition for the parenteral administration of ultrashort-effective β-adrenoreceptor antagonists
WO2009079679A3 (de) * 2007-12-21 2009-11-26 Aop Orphan Pharmaceuticals Ag Pharmazeutische zusammensetzung zur parenteralen verabreichung eines ultrakurzwirksamξn beta-adrenorezeptor antagonisten
US10660964B2 (en) 2007-12-21 2020-05-26 Aop Orphan Pharmaceuticals Ag Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
AU2009293400B2 (en) * 2008-09-19 2015-05-07 Novartis Ag Stabilized pharmaceutical sub-micron suspensions and methods of forming same
EP2425815A1 (en) * 2008-09-19 2012-03-07 Alcon Research, Ltd. Stabilized pharmaceutical sub-micron suspensions and methods of forming same
JP2012503003A (ja) * 2008-09-19 2012-02-02 アルコン リサーチ， リミテッド 安定化された薬学的サブミクロン懸濁物およびその形成方法
CN104688682A (zh) * 2008-09-19 2015-06-10 爱尔康研究有限公司 稳定的药物亚微米悬浮剂及其制备方法
RU2521258C2 (ru) * 2008-09-19 2014-06-27 Алькон Рисерч, Лтд. Стабилизированные фармацевтические субмикронные суспензии и способы их получения
WO2010033528A1 (en) 2008-09-19 2010-03-25 Alcon Research, Ltd. Stabilized pharmaceutical sub-micron suspensions and methods of forming same
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
US9851351B2 (en) 2009-01-29 2017-12-26 Forsight Vision4, Inc. Posterior segment drug delivery
US10656152B2 (en) 2009-01-29 2020-05-19 Forsight Vision4, Inc. Posterior segment drug delivery
US10813788B2 (en) 2009-01-29 2020-10-27 Forsight Vision4, Inc. Implantable therapeutic device
US11642310B2 (en) 2009-01-29 2023-05-09 Forsight Vision4, Inc. Posterior segment drug delivery
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011113904A1 (en) * 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US9861521B2 (en) 2010-08-05 2018-01-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US11679027B2 (en) 2010-08-05 2023-06-20 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10265215B2 (en) 2010-08-05 2019-04-23 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US11786396B2 (en) 2010-08-05 2023-10-17 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US11065151B2 (en) 2010-11-19 2021-07-20 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US11813196B2 (en) 2011-06-28 2023-11-14 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10653554B2 (en) 2011-09-16 2020-05-19 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
RU2672596C2 (ru) * 2012-01-23 2018-11-16 Аллерган, Инк. Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10603209B2 (en) 2012-02-03 2020-03-31 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US12115102B2 (en) 2013-03-28 2024-10-15 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10398593B2 (en) 2013-03-28 2019-09-03 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US11510810B2 (en) 2013-03-28 2022-11-29 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US12343283B2 (en) 2014-07-15 2025-07-01 Forsight Vision4, Inc. Ocular implant delivery device and method
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
US11337853B2 (en) 2014-07-15 2022-05-24 Forsight Vision4, Inc. Ocular implant delivery device and method
US10363255B2 (en) 2014-08-08 2019-07-30 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9895369B2 (en) 2014-08-08 2018-02-20 Forsight Vision4, Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10765677B2 (en) 2014-08-08 2020-09-08 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US11110001B2 (en) 2014-11-10 2021-09-07 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US12251336B2 (en) 2014-11-10 2025-03-18 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US12186424B2 (en) 2015-06-06 2025-01-07 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium recurrence
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US12201556B2 (en) 2015-11-20 2025-01-21 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US12102560B2 (en) 2016-04-05 2024-10-01 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
EP4194011A1 (en) * 2016-11-29 2023-06-14 Oculis SA Preparation of cyclodextrin nanoparticle for ophthalmic drug delivery
WO2019043169A1 (en) * 2017-09-01 2019-03-07 Murray & Poole Enterprises, Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS
US11000530B2 (en) 2017-09-01 2021-05-11 Murray And Poole Enterprises Ltd Methods and compositions for the treatment of ophthalmic conditions
JP2020535217A (ja) * 2017-09-01 2020-12-03 マリー アンド プール エンタープライゼズ，リミテッド 眼病態を治療するための方法および組成物
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
EP4121417A4 (en) * 2020-05-01 2023-08-09 University Of Southern California CYCLODEXTRIN-BASED ANTIMICROBIAL THERAPY
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
WO2023148231A1 (en) * 2022-02-02 2023-08-10 Oculis SA Multidose ophthalmic compositions
WO2025082585A1 (en) 2023-10-16 2025-04-24 Oculis Operations Sàrl Method of treating diabetic macular edema
WO2025083031A1 (en) 2023-10-16 2025-04-24 Oculis Operations Sàrl Method of treating diabetic macular edema
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Also Published As

Publication number Publication date
US20120028944A1 (en) 2012-02-02
US7893040B2 (en) 2011-02-22
EP1909755B1 (en) 2018-04-25
EP1909755A2 (en) 2008-04-16
US20070020336A1 (en) 2007-01-25
ES2675043T3 (es) 2018-07-06
US20140186443A1 (en) 2014-07-03
US20130142791A1 (en) 2013-06-06
US8999953B2 (en) 2015-04-07
PL1909755T3 (pl) 2018-10-31
WO2007012974A3 (en) 2007-07-12
US8633172B2 (en) 2014-01-21

Similar Documents

Publication Publication Date Title
US8999953B2 (en) Cyclodextrin nanotechnology for ophthalmic drug delivery
Gaballa et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives
Lanier et al. Review of approaches for increasing ophthalmic bioavailability for eye drop formulations
Loftsson et al. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops
JP5583145B2 (ja) レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物
Loftssona et al. Cyclodextrins in ophthalmic drug delivery
Loftsson et al. Aqueous eye drops containing drug/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment
US20070149480A1 (en) PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070224278A1 (en) Low immunogenicity corticosteroid compositions
US20110212142A1 (en) Curcuminoids and its metabolites for the application in ocular diseases
US20060141049A1 (en) Triamcinolone compositions for intravitreal administration to treat ocular conditions
Maharjan et al. Pharmaceutical challenges and perspectives in developing ophthalmic drug formulations
AU2017360116B2 (en) Ophthalmic compositions comprising a cyclodextrin as sole active agent
JP2017524712A (ja) 角膜同種移植片拒絶および新血管形成を予防するためのグルココルチコイドを負荷したナノ粒子
JP6214726B2 (ja) スクアラミンの眼用製剤
TW202342108A (zh) 多劑量眼用組成物
Loftsson et al. Dexamethasone delivery to posterior segment of the eye
US10744153B1 (en) Compositions and methods for treating meibomian gland dysfunction
AU2015258244B2 (en) Ophthalmic formulations of squalamine
HK1228731A1 (en) Ophthalmic formulations of squalamine
HK1185566A (en) Ophthalmic formulations of squalamine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006808951

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006808951

Country of ref document: EP